全球白細胞介素-2市場：區域分析與預測（2025-2035年）

白細胞介素-2（IL-2）是細胞激素，可促進 T 細胞（對免疫反應非常重要的白血球）的增殖和分化。

IL-2 具有巨大的治療潛力，尤其是在癌症免疫療法和自體免疫疾病的治療中。在免疫腫瘤學的進展、免疫調節研究的不斷深入以及對細胞激素治療重要性的重新評估的背景下，基於 IL-2 的治療方法市場蓬勃發展。先前已獲 FDA核准的IL-2 療法，例如Aldesleukin (Proleukin) ，已用於治療轉移性黑色素瘤和腎細胞癌（RCC），是癌症免疫治療領域的重要里程碑。近年來，新的製劑和標靶 IL-2 療法不斷湧現，有望改善各種癌症和自體免疫疾病的治療效果。

由於細胞激素激素療法的進步、癌症免疫療法應用的不斷拓展以及對免疫調節療法的需求不斷成長，全球IL-2市場穩步成長。 IL-2在癌症治療中的作用以及在治療慢性自體免疫疾病方面的潛力，使其成為現代醫學研究和藥物開發的重點領域。

市場的主要成長要素之一是癌症發生率的上升。由於黑色素瘤、腎細胞癌和固體癌的發生率上升，全球癌症負擔持續上升。 IL-2已證明能夠增強針對這些傳統化療難以治療的癌症的免疫反應。因此，隨著癌症發生率的上升，對創新癌症免疫療法的需求日益成長，尤其是基於IL-2的治療方法。

此外，對免疫療法研發的大量投資也推動了 IL-2 市場的強勁成長。製藥公司和研究機構投入大量資源開發更有效、更安全的IL-2治療方法，因為人們越來越認知到免疫腫瘤療法在治療難治性癌症方面已顯示出療效。 FDA 和 EMA 等政府和監管機構也積極支持包括 IL-2 療法在內的免疫療法的開發和核准，這有助於推動市場擴張。例如，NKTR-214 是一種基於 IL-2 的新型治療藥物，目的是與其他免疫療法聯合使用，作為目的是為癌症患者提供持續治療效果的新一代治療方法，它的核准加速進一步的市場擴張。

本報告調查了全球白細胞介素-2市場，並總結了主要趨勢、影響市場的因素分析、法律制度、臨床試驗趨勢、市場規模趨勢和預測、各個細分市場、地區/主要國家的詳細分析、競爭格局和主要企業的概況。

目錄

執行摘要

第1章 全球白細胞介素-2市場：產業展望

• 市場趨勢
• 法律規範
• 臨床試驗分析
• 市場動態
  • 影響分析
  • 市場促進因素
  • 市場挑戰
  • 市場機會

第2章 全球白細胞介素-2 市場：依地區

• 北美洲
• 歐洲
• 亞太地區
  • 主要調查結果
  • 市場動態
  • 市場規模及預測

第3章 全球白細胞介素-2 市場：競爭格局與公司概況

• 主要發展和策略
  • M&A
  • 協同努力
  • 業務擴展和資金籌措
  • 產品發布和核准
  • 其他活動
• 公司簡介
  • Bristol Myers Squibb
  • Sanofi SA
  • Corvus Pharmaceuticals
  • Regeneron Pharmaceuticals
  • Merck & Co., Inc.
  • F. Hoffmann-La Roche AG
  • Cue Biopharma

第4章 調查方法

Global Interleukin-2 Market, Analysis and Forecast: 2025-2035

Interleukin-2 (IL-2) is a cytokine that plays a crucial role in the immune system by promoting the growth and differentiation of T cells, a type of white blood cell that is essential for immune responses. IL-2 has significant therapeutic applications, particularly in cancer immunotherapy and autoimmune diseases. The market for IL-2-based therapies has been evolving, driven by advancements in immuno-oncology, increased research into immune modulation, and the growing recognition of the importance of cytokine-based therapies in treating various conditions. Historically, IL-2 therapies such as Aldesleukin (Proleukin), approved by the FDA, have been used primarily for treating metastatic melanoma and renal cell carcinoma (RCC), marking significant milestones in immunotherapy. However, newer formulations and targeted IL-2 therapies are emerging, offering the potential to improve outcomes in various cancers and autoimmune disorders.

The global IL-2 market is growing steadily, fueled by advancements in cytokine-based treatments, expanding applications in cancer immunotherapy, and the increasing demand for immunomodulatory treatments. IL-2's role in cancer treatment and its potential in managing chronic autoimmune diseases make it a vital area of focus in modern medical research and pharmaceutical development.

One of the key drivers of the market is the rising prevalence of cancer. The global cancer burden continues to rise, with increasing rates of melanoma, renal cell carcinoma, and solid tumors. IL-2 has been shown to improve the immune response in cancers that are traditionally hard to treat with standard chemotherapy. As cancer incidence increases, there is a growing demand for innovative immunotherapies, including IL-2-based treatments.

Moreover, the IL-2 market is experiencing robust growth due to significant investments in immunotherapy research. Pharmaceutical companies and research institutions are pouring resources into the development of more effective and safer IL-2 therapies. This investment is driven by the increasing recognition of the effectiveness of immuno-oncology treatments in treating cancers that were previously difficult to manage. In addition, governments and regulatory bodies, such as the FDA and EMA, are offering more support for the development and approval of immunotherapies, including IL-2 treatments. The approval of new IL-2-based therapies such as NKTR-214 for use in combination with other immunotherapies has further propelled the market, as these therapies aim to provide more durable responses for cancer patients.

Despite the promising potential of IL-2 therapies, their high cost remains a significant barrier to widespread adoption. Aldesleukin (Proleukin), for example, is expensive, and while newer engineered IL-2 treatments may offer better outcomes, they come with high price tags that limit their accessibility, particularly in developing regions or for patients without insurance coverage. Also, high-dose IL-2 therapy is associated with severe side effects, including fever, chills, nausea, hypotension, and organ toxicity. These side effects can deter patients from undergoing treatment and limit the overall efficacy of IL-2-based therapies, especially in the long term. Efforts are ongoing to engineer IL-2 variants that retain efficacy while minimizing toxicities, but the challenge remains a restraint on market growth.

The global Interleukin-2 (IL-2) market is evolving rapidly, with major pharmaceutical companies and emerging biotech firms driving innovation. The market is highly fragmented, with significant ongoing research into expanding IL-2's use in treating cancer and autoimmune disorders such as lupus and multiple sclerosis. Companies are increasingly focusing on improving patients' quality of life by addressing immune-related issues alongside disease treatment, marking a transformative phase for the IL-2 market.

The Interleukin-2 (IL-2) market is undergoing significant transformation, driven by emerging trends in immunotherapy and advancements in biotechnology. One of the key trends is the increasing focus on personalized medicine, where IL-2 treatment plans are being tailored to individual patients' genetic profiles, disease progression, and immune system responses. With a deeper understanding of the molecular mechanisms behind diseases such as cancer and autoimmune disorders, biotech companies are investing in genetic research and biomarkers to identify which patients are most likely to benefit from IL-2-based therapies. This personalized approach has the potential to optimize treatment outcomes, minimize side effects, and improve overall patient well-being.

Another major trend is the growing demand for engineered IL-2 therapies that are more targeted and effective compared to traditional formulations. Engineered IL-2s such as NKTR-214 (bempegaldesleukin) are designed to enhance the selective activation of the immune system, particularly in tumor environments. These therapies have shown promising results in clinical trials, especially when combined with checkpoint inhibitors such as PD-1/PD-L1 inhibitors. IL-2-based combination therapies are gaining traction in oncology, especially for the treatment of solid tumors, where traditional therapies have shown limited success. Additionally, there is increasing interest in non-cancerous applications of IL-2, including its potential for managing autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis.

As healthcare access expands globally, the demand for IL-2 therapies is expected to rise, particularly in emerging markets where immunotherapy treatments are becoming more accessible. Pharmaceutical companies are focusing on improving affordability through patient assistance programs, pricing strategies, and distribution partnerships. These efforts aim to make IL-2-based therapies more widely available, especially in low- and middle-income regions, where the demand for effective treatments for cancer and autoimmune diseases is increasing. Furthermore, the rise of digital health tools and telemedicine platforms is enhancing the management of IL-2 therapies. These tools allow healthcare providers to remotely monitor patient responses, adjust treatment regimens, and ensure better patient adherence, particularly in long-term treatment scenarios.

In conclusion, the Interleukin-2 (IL-2) market is poised for continued growth, driven by innovations in engineered IL-2 therapies, personalized medicine, and increased access to cutting-edge treatments worldwide. While challenges such as the high cost of biologic therapies and side effects persist, ongoing research into more targeted and safer IL-2 therapies offers hope for improved treatment outcomes. With increasing global healthcare access, the market is positioned for expansion, especially as IL-2 therapies are incorporated into combination treatments and new therapeutic areas, such as autoimmune diseases. As innovation continues, both large pharmaceutical companies and emerging biotech firms will fuel competition, ultimately improving the quality of life for patients undergoing IL-2-based treatments.

Table of Contents

Executive Summary

Scope and Definition

Market/Product Definition

Inclusion and Exclusion

Key Questions Answered

Analysis and Forecast Note

1. Global Interleukin-2 Market: Industry Outlook

• 1.1 Introduction
• 1.2 Market Trends
• 1.3 Regulatory Framework
• 1.4 Clinical Trial Analysis
• 1.5 Market Dynamics
  • 1.5.1 Impact Analysis
  • 1.5.2 Market Drivers
  • 1.5.3 Market Challenges
  • 1.5.4 Market Opportunities

2. Global Interleukin-2 Market, by Region, $Million, 2023-2035

• 2.1 North America
  • 2.1.1 Key Findings
  • 2.1.2 Market Dynamics
  • 2.1.3 Market Sizing and Forecast
    • 2.1.3.1 North America Interleukin-2 Market, by Country
      • 2.1.3.1.1 U.S.
• 2.2 Europe
  • 2.2.1 Key Findings
  • 2.2.2 Market Dynamics
  • 2.2.3 Market Sizing and Forecast
    • 2.2.3.1 Europe Interleukin-2 Market, by Country
      • 2.2.3.1.1 Germany
      • 2.2.3.1.2 U.K.
      • 2.2.3.1.3 France
      • 2.2.3.1.4 Italy
      • 2.2.3.1.5 Spain
• 2.3 Asia Pacific
  • 2.3.1 Key Findings
  • 2.3.2 Market Dynamics
  • 2.3.3 Market Sizing and Forecast
    • 2.3.3.1 Asia Pacific Interleukin-2 Market, by Country
      • 2.3.3.1.1 Japan

3. Global Interleukin-2 Market: Competitive Landscape and Company Profiles

• 3.1 Key Development and Strategies
  • 3.1.1 Mergers and Acquisitions
  • 3.1.2 Synergistic Activities
  • 3.1.3 Business Expansions and Funding
  • 3.1.4 Product Launches and Approvals
  • 3.1.5 Other Activities
• 3.2 Company Profiles
  • 3.2.1 Bristol Myers Squibb
    • 3.2.1.1 Overview
    • 3.2.1.2 Top Products / Product Portfolio
    • 3.2.1.3 Target Customers/End-Users
    • 3.2.1.4 Key Personnel
    • 3.2.1.5 Analyst View
  • 3.2.2 Sanofi S.A.
    • 3.2.2.1 Overview
    • 3.2.2.2 Top Products / Product Portfolio
    • 3.2.2.3 Target Customers/End-Users
    • 3.2.2.4 Key Personnel
    • 3.2.2.5 Analyst View
  • 3.2.3 Corvus Pharmaceuticals
    • 3.2.3.1 Overview
    • 3.2.3.2 Top Products / Product Portfolio
    • 3.2.3.3 Target Customers/End-Users
    • 3.2.3.4 Key Personnel
    • 3.2.3.5 Analyst View
  • 3.2.4 Regeneron Pharmaceuticals
    • 3.2.4.1 Overview
    • 3.2.4.2 Top Products / Product Portfolio
    • 3.2.4.3 Target Customers/End-Users
    • 3.2.4.4 Key Personnel
    • 3.2.4.5 Analyst View
  • 3.2.5 Merck & Co., Inc.
    • 3.2.5.1 Overview
    • 3.2.5.2 Top Products / Product Portfolio
    • 3.2.5.3 Target Customers/End-Users
    • 3.2.5.4 Key Personnel
    • 3.2.5.5 Analyst View
  • 3.2.6 F. Hoffmann-La Roche AG
    • 3.2.6.1 Overview
    • 3.2.6.2 Top Products / Product Portfolio
    • 3.2.6.3 Target Customers/End-Users
    • 3.2.6.4 Key Personnel
    • 3.2.6.5 Analyst View
  • 3.2.7 Cue Biopharma
    • 3.2.7.1 Overview
    • 3.2.7.2 Top Products / Product Portfolio
    • 3.2.7.3 Target Customers/End-Users
    • 3.2.7.4 Key Personnel
    • 3.2.7.5 Analyst View

4. Research Methodology

List of Figures

• Figure: Global Interleukin-2 Market (by Region), $Million, 2024 and 2035
• Figure: Global Interleukin-2 Market Key Trends, Impact Analysis,

List of Tables

• Table: Global Interleukin-2 Market Dynamics, Impact Analysis
• Table: Global Interleukin-2 Market (by Region), $Million, 2023-2035